{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:56:12Z","timestamp":1794938172965,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"NHLBI\/NIH","award":["R01 HL089758"],"award-info":[{"award-number":["R01 HL089758"]}]},{"name":"NHLBI\/NIH","award":["R01 HL089901"],"award-info":[{"award-number":["R01 HL089901"]}]},{"DOI":"10.13039\/100001844","name":"Scleroderma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001844","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NIAMS","award":["K23AR061436"],"award-info":[{"award-number":["K23AR061436"]}]},{"name":"NIH\/NIAMS","award":["K24 AR063120"],"award-info":[{"award-number":["K24 AR063120"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-1203-y","type":"journal-article","created":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T12:20:33Z","timestamp":1483100433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Elizabeth R.","family":"Volkmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Mayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hong","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Elashoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,30]]},"reference":[{"key":"1203_CR1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809\u201315.","journal-title":"Ann Rheum Dis."},{"key":"1203_CR2","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.lpm.2014.08.002","volume":"43","author":"AU Wells","year":"2014","unstructured":"Wells AU. Interstitial lung disease in systemic sclerosis. Press Med. 2014;43:e329\u201343.","journal-title":"Press Med."},{"key":"1203_CR3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/ard.62.2.146","volume":"62","author":"C Morgan","year":"2003","unstructured":"Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis. 2003;62:146\u201350.","journal-title":"Ann Rheum Dis."},{"key":"1203_CR4","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.22099","volume":"55","author":"SC Plastiras","year":"2006","unstructured":"Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 2006;55:598\u2013602.","journal-title":"Arthritis Rheum."},{"key":"1203_CR5","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","volume":"66","author":"SI Nihtyanova","year":"2014","unstructured":"Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014;66:1625\u201335.","journal-title":"Arthritis Rheumatol."},{"key":"1203_CR6","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","volume":"43","author":"VD Steen","year":"2000","unstructured":"Steen VD, Medsger Jr TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437\u201344.","journal-title":"Arthritis Rheum."},{"key":"1203_CR7","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NSL Goh","year":"2008","unstructured":"Goh NSL, Desai SR, Veeraraghaven S, et al. Interstitial lung disease in systemic sclerosis. A simple staging system. Am J Respir Crit Care Med. 2008;177:1248\u201354.","journal-title":"Am J Respir Crit Care Med"},{"key":"1203_CR8","first-page":"378","volume":"165","author":"OA Moore","year":"2013","unstructured":"Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution compute tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). 2013;165:378\u201381.","journal-title":"Rheumatology (Oxford)"},{"key":"1203_CR9","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3125","volume":"12","author":"S Assassi","year":"2010","unstructured":"Assassi S, Sharif R, Lasky RE, et al. GENISOS Study Group. Arthritis Res Ther. 2010;12:R166.","journal-title":"Arthritis Res Ther."},{"key":"1203_CR10","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/art.30438","volume":"63","author":"MD Roth","year":"2011","unstructured":"Roth MD, Tseng CH, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum. 2011;63:2797\u2013808.","journal-title":"Arthritis Rheum."},{"key":"1203_CR11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","volume":"40","author":"A Lauretis De","year":"2013","unstructured":"De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40:435\u201346.","journal-title":"J Rheumatol."},{"key":"1203_CR12","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","volume":"65","author":"X Liu","year":"2013","unstructured":"Liu X, Mayes MD, Pedroza C, et al. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res. 2013;65:1375\u201380.","journal-title":"Arthritis Care Res."},{"key":"1203_CR13","first-page":"S742","volume":"65","author":"M Wu","year":"2013","unstructured":"Wu M, Pedroza C, Salazar G, et al. Plasma MCP-1 and IL-10 levels predict long-term progression of interstitial lung disease in patients with early systemic sclerosis. Arthritis Rheum. 2013;65:S742.","journal-title":"Arthritis Rheum."},{"key":"1203_CR14","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1183\/09031936.00004711","volume":"38","author":"KP Tiev","year":"2011","unstructured":"Tiev KP, Hua-Huy T, Kettaneh A, et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir. 2011;38:1355\u201360.","journal-title":"Eur Respir."},{"key":"1203_CR15","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1183\/09031936.00131713","volume":"43","author":"J Schupp","year":"2014","unstructured":"Schupp J, Becker M, G\u00fcnther J, et al. Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. Eur Respir J. 2014;43:1530\u20132.","journal-title":"Eur Respir J."},{"key":"1203_CR16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","volume":"370","author":"L Bon van","year":"2014","unstructured":"van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014;370:433\u201343.","journal-title":"N Engl J Med."},{"key":"1203_CR17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"T Masi","year":"1980","unstructured":"Masi T. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheumatol. 1980;23:581\u201390.","journal-title":"Arthritis Rheumatol"},{"key":"1203_CR18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","volume":"85","author":"DA Mahler","year":"1984","unstructured":"Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest. 1984;85:751\u20138.","journal-title":"Chest"},{"key":"1203_CR19","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al., for the Scleroderma Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: Scleroderma lung study II (SLS-II), a double-blind, parallel group, mmunomodu controlled trial. Lancet Resp Med. 2016. [Epub ahead of print]"},{"key":"1203_CR20","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.acra.2008.03.011","volume":"15","author":"HJ Kim","year":"2008","unstructured":"Kim HJ, Li G, Gjertson D, et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol. 2008;15:1004\u201316.","journal-title":"Acad Radiol."},{"key":"1203_CR21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/hep.23435","volume":"51","author":"MM Zaldivar","year":"2010","unstructured":"Zaldivar MM, Pauels K, von Hundelshausen P, et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology. 2010;51:1345\u201353.","journal-title":"Hepatology."},{"key":"1203_CR22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jaut.2015.08.001","volume":"65","author":"MD Patsouras","year":"2015","unstructured":"Patsouras MD, Skiara MP, Grikak EP, et al. Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome. J Autoimmun. 2015;65:30\u20137.","journal-title":"J Autoimmun."},{"key":"1203_CR23","volume-title":"Low heme oxygenase-1 levels in patients with systemic sclerosis are associated with an altered Toll-like receptor response: another role for CXCL4? Rheumatol (Oxford)","author":"L Bon van","year":"2016","unstructured":"van Bon L, Cossu M, Scharstuhl A, et al. Low heme oxygenase-1 levels in patients with systemic sclerosis are associated with an altered Toll-like receptor response: another role for CXCL4? Rheumatol (Oxford). 2016 [Epub ahead of print]."},{"key":"1203_CR24","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/ar2821","volume":"11","author":"P Gourh","year":"2009","unstructured":"Gourh P, Arnett FC, Assassi S, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther. 2009;11:R147.","journal-title":"Arthritis Res Ther."},{"key":"1203_CR25","unstructured":"R&D Systems: Quantikine ELISA Human CXCL4\/PF4 Immunoassay. https:\/\/resources.rndsystems.com\/pdfs\/datasheets\/dpf40.pdf (2016). Accessed 13 Sep 2016."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-1203-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:04:40Z","timestamp":1498359880000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-1203-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1203"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-1203-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"article-number":"305"}}